Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9302990 | 0.89 | CA1 (0.60) | PYGBGAACA1CA2CA9 | |
| SCHEMBL9302995 | 0.89 | CA1 (0.60) | PYGBGAACA1CA2CA9 | |
| SCHEMBL18934182 | 0.87 | PYGB (0.68) | PYGBGAACA1CA2CA9 | |
| SCHEMBL16664307 | 0.87 | CA1 (0.53) | PYGBGAACA1CA2CA9 | |
| SCHEMBL16190468 | 0.87 | PYGB (0.68) | PYGBGAACA1CA2CA9 | |
| SCHEMBL14750544 | 0.87 | PYGB (0.68) | PYGBGAACA1CA2CA9 | |
| SCHEMBL15975750 | 0.86 | PYGB (0.67) | PYGBGAACA1CA2CA9 | |
| SCHEMBL4173063 | 0.84 | PYGB (0.97) | PYGBGAACA1CA2CA9 | |
| SCHEMBL4184772 | 0.84 | PYGB (0.97) | PYGBGAACA1CA2CA9 | |
| SCHEMBL16217898 | 0.84 | ALDH1A1 (0.54) | PYGBGAACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218342-A1 | SITE-SPECIFIC GLYCAN REMODELING OF LYSOSOMAL ENZYMES AND APPLICATIONS THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2024-07-04 | — | — | US | disclosed |
| US-7728106-B2 | HIV-1 glycopeptides and derivatives; preparation and applications thereof | UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070224211-A1 | HIV-1 glycopeptides and derivatives; preparation and applications thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218342-A1 | SITE-SPECIFIC GLYCAN REMODELING OF LYSOSOMAL ENZYMES AND APPLICATIONS THEREOF | GAA, MAN2B1, M6PR | PYGB 281/4885GAA 1/4885CA1 2735/4885 |
| US-20070224211-A1 | HIV-1 glycopeptides and derivatives; preparation and applications thereof | ENGASE, GALE, CD4 | PYGB 935/4885GAA 132/4885CA1 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.